IRON (Disc Medicine, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by IRON officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Kevin Bitterman | Director | Sell | — | — |
| 2026-08-26 | Jonathan Yen-Wen Yu | Chief Operating Officer | MIXED | — | — |
| 2026-08-18 | John D Quisel | Chief Executive Officer | MIXED | — | — |
| 2026-08-14 | Jonathan Yen-Wen Yu | Chief Operating Officer | MIXED | — | — |
| 2026-08-07 | Rahul Khara | Chief Legal Officer | MIXED | — | — |
| 2026-08-07 | Rahul Khara | Chief Legal Officer | MIXED | — | — |
| 2026-07-14 | John D Quisel | Chief Executive Officer | MIXED | — | — |
| 2026-07-09 | Jonathan Yen-Wen Yu | Chief Operating Officer | MIXED | — | — |
| 2026-06-24 | Jonathan Yen-Wen Yu | Chief Operating Officer | MIXED | — | — |
| 2026-06-23 | Kevin Bitterman | Director | A | — | — |
| 2026-06-23 | Liam Ratcliffe | Director | A | — | — |
| 2026-06-23 | William Richard White | Director | A | — | — |
| 2026-06-23 | NADIM AHMED | Director | A | — | — |
| 2026-06-23 | GEORGES GEMAYEL | Director | A | — | — |
| 2026-06-23 | Donald William Nicholson | Director | A | — | — |
| 2026-06-23 | Mark Chin | Director | A | — | — |
| 2026-06-23 | Rahul Khara | Chief Legal Officer | MIXED | — | — |
| 2026-06-23 | John D Quisel | Chief Executive Officer | MIXED | — | — |
| 2026-06-18 | Jonathan Yen-Wen Yu | Chief Operating Officer | MIXED | — | — |
| 2026-04-15 | William Jacob Savage | Chief Medical Officer | Sell | — | — |
| 2026-04-15 | Jean M. Franchi | Chief Financial Officer | Sell | — | — |
| 2026-03-04 | William Jacob Savage | Chief Medical Officer | Sell | — | — |
| 2026-02-27 | Jean M. Franchi | Chief Financial Officer | Sell | — | — |
| 2026-02-19 | Jean M. Franchi | Chief Financial Officer | Sell | — | — |
| 2026-02-17 | Rahul Khara | Chief Legal Officer | Sell | — | — |
| 2026-02-17 | William Jacob Savage | Chief Medical Officer | Sell | — | — |
| 2026-02-17 | John D Quisel | Chief Executive Officer | Sell | — | — |
| 2026-02-17 | Pamela Stephenson | Chief Commercial Officer | Sell | — | — |
| 2026-02-17 | Jonathan Yen-Wen Yu | Chief Operating Officer | Sell | — | — |
| 2026-02-11 | William Jacob Savage | Chief Medical Officer | A | — | — |
| 2026-02-11 | Pamela Stephenson | Chief Commercial Officer | A | — | — |
| 2026-02-11 | Rahul Khara | Chief Legal Officer | A | — | — |
| 2026-02-11 | Jean M. Franchi | Chief Financial Officer | A | — | — |
| 2026-02-11 | Jonathan Yen-Wen Yu | Chief Operating Officer | A | — | — |
| 2026-02-11 | John D Quisel | Chief Executive Officer | A | — | — |
| 2026-01-21 | Rahul Khara | Chief Legal Officer | MIXED | — | — |
| 2026-01-05 | Rahul Khara | Chief Legal Officer | MIXED | — | — |
| 2025-12-29 | William Jacob Savage | Chief Medical Officer | M | — | — |
| 2025-12-19 | John D Quisel | Chief Executive Officer | M | — | — |
| 2025-12-18 | Kevin Bitterman | Director | Sell | — | — |
| 2025-12-16 | William Jacob Savage | Chief Medical Officer | Sell | — | — |
| 2025-12-16 | Kevin Bitterman | Director | MIXED | — | — |
| 2025-12-15 | John D Quisel | Chief Executive Officer | MIXED | — | — |
| 2025-11-13 | Jonathan Yen-Wen Yu | Chief Operating Officer | MIXED | — | — |
| 2025-10-24 | Access Industries Holdings LLC | 10%+ Owner | Sell | — | — |
| 2025-10-17 | Kevin Bitterman | Director | Sell | — | — |
| 2025-10-09 | Kevin Bitterman | Director | Sell | — | — |
| 2025-09-18 | GEORGES GEMAYEL | Director | A | — | — |
| 2025-09-11 | John D Quisel | Chief Executive Officer | M | — | — |
| 2025-08-26 | Kevin Bitterman | Director | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 3,558,426 | — |
| — | 10%+ Owner | 2,814,379 | — |
| — | 10%+ Owner | 2,347,367 | — |
| — | 10%+ Owner | 2,235,846 | — |
| — | 10%+ Owner | 2,105,846 | — |
| — | 10%+ Owner | 1,090,772 | — |
| — | Director | 899,349 | — |
| — | Director | 776,844 | — |
| — | Director | 746,171 | — |
| — | Director | 608,611 | — |
| — | Director | 484,032 | — |
| — | Director | 312,989 | — |
| — | Chief Executive Officer | 226,064 | — |
| — | Chief Commercial Officer | 80,998 | — |
| — | Chief Medical Officer | 79,480 | — |
| — | Chief Financial Officer | 70,590 | — |
| — | Chief Legal Officer | 57,324 | — |
| — | Chief Operating Officer | 54,624 | — |
| — | Chief Innovation Officer | 26,249 | — |
| — | Chief Financial Officer | 23,665 | — |
| — | Director | 1,756 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IRON quote page; the site-wide leaderboard is on the insider transactions hub.